Advertisement Alitair benzonatate formulation now eligible for Rx-to-OTC switch - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

Alitair benzonatate formulation now eligible for Rx-to-OTC switch

Early stage pharmaceutical company Alitair Pharmaceuticals will offer benzonatate formulation with Rx-to-OTC switch potential.

Alitair provided additional details regarding its ‘398 patent specific to formulations of benzonatate.

At present, benzonatate is the only non-narcotic prescription cough product available, according to the company

The tablet eliminates the potential for numbing, thus reducing or eliminating the danger of choking.